• 00Days
  • 00Hrs
  • 00Mins
  • 00Secs

Chair: Anna TAN (Singapore)

Date & Time: Friday, 24 July 2026, 1245 – 1345 hrs         Venue: Level 3, Meeting Room 333

The management of retinal diseases continues to evolve, with emerging evidence reshaping how clinicians approach treatment decisions. This symposium convenes leading retinal specialists to review the latest clinical evidence on aflibercept 8mg and its implications for sustained visual outcomes. Join us to explore how current data can be translated into confident, everyday clinical practice for your patients.

Time Presentation Topic Speaker
1245 – 1250 Welcome & Introduction Anna TAN (Singapore)
1250 – 1300 Advancing the Next Era – Aflibercept 8mg in Focus Anna TAN (Singapore)
1300 – 1330 Translating Evidence into Practice:

Confidence in nAMD with Aflibercept 8mg
PCV Treatment Reimagined with Aflibercept 8mg
Real-World DME: Drying Beyond Expectations

 

CHAN Hiok Hong (Singapore)
Ranjana MATHUR (Singapore)
Gavin TAN (Singapore)

1330 – 1345 Q&A

Closing

All

Anna TAN (Singapore)

Abstract submission deadline extended

Important dates
Good News! Abstract Submission Now Open Until 21 February 2026